Empagliflozin

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 5465 publications

Adjunctive Treatments for Patients with Type 1 Diabetes Using Automated Insulin Delivery Systems. A Narrative Review.

Adjunctive Treatments for Patients with Type 1 Diabetes Using Automated Insulin Delivery Systems. A Narrative Review.

Journal: Diabetes technology & therapeutics

Published: September 04, 2026

Mechanism of Shengqing Jiangzhuo Granules in ameliorating chronic functional constipation with dampness obstruction and Qi stagnation pattern and associated hyperuricemia based on "gut-microbiota-barrier" axis

Mechanism of Shengqing Jiangzhuo Granules in ameliorating chronic functional constipation with dampness obstruction and Qi stagnation pattern and associated hyperuricemia based on "gut-microbiota-barrier" axis

Journal: Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica

Published: September 03, 2026

Finerenone Plus Empagliflozin: How Low Can We Go, and How Much Does Blood Pressure Matter?

Finerenone Plus Empagliflozin: How Low Can We Go, and How Much Does Blood Pressure Matter?

Journal: Hypertension (Dallas, Tex. : 1979)

Published: August 19, 2026

Empagliflozin Reduces Post-Myocardial Infarction Inflammation via BDH1/β-Hydroxybutyrate-Mediated NF-κB Modulation in Macrophages and the Heart.

Empagliflozin Reduces Post-Myocardial Infarction Inflammation via BDH1/β-Hydroxybutyrate-Mediated NF-κB Modulation in Macrophages and the Heart.

Journal: Journal of cardiovascular pharmacology

Published: August 12, 2026

Linagliptin attenuates cisplatin-induced cardiotoxicity in rats via modulation of the SIRT1/AMPK/Nrf2 signaling pathway.

Linagliptin attenuates cisplatin-induced cardiotoxicity in rats via modulation of the SIRT1/AMPK/Nrf2 signaling pathway.

Journal: Drug and chemical toxicology

Published: August 11, 2026

Early-Onset Euglycemic Diabetic Ketoacidosis Following Empagliflozin Initiation Triggered by Acute Influenza and a Ketogenic Diet.

Early-Onset Euglycemic Diabetic Ketoacidosis Following Empagliflozin Initiation Triggered by Acute Influenza and a Ketogenic Diet.

Journal: Cureus

Published: August 09, 2026

Empagliflozin Attenuates Ferroptosis in Acute Myocardial Infarction via the AMPK/NRF2/SLC7A11 Signaling Pathway.

Empagliflozin Attenuates Ferroptosis in Acute Myocardial Infarction via the AMPK/NRF2/SLC7A11 Signaling Pathway.

Journal: International heart journal

Published: August 03, 2026

Development and validation of a stability-indicating LC-MS/MS method for simultaneous estimation of empagliflozin and metoprolol in pharmaceutical dosage forms with forced degradation studies and computational assessment of degradation products.

Development and validation of a stability-indicating LC-MS/MS method for simultaneous estimation of empagliflozin and metoprolol in pharmaceutical dosage forms with forced degradation studies and computational assessment of degradation products.

Journal: The Analyst

Published: July 29, 2026

Longitudinal Assessment of Diastolic Function and Myocardial Strain in Type 2 Diabetes: A Comparison of Empagliflozin and Linagliptin.

Longitudinal Assessment of Diastolic Function and Myocardial Strain in Type 2 Diabetes: A Comparison of Empagliflozin and Linagliptin.

Journal: Anatolian journal of cardiology

Published: July 27, 2026

Empagliflozin Ameliorates Experimental Pulmonary Vascular Remodeling, but May Not Benefit Patients With Pulmonary Arterial Hypertension.

Empagliflozin Ameliorates Experimental Pulmonary Vascular Remodeling, but May Not Benefit Patients With Pulmonary Arterial Hypertension.

Journal: Journal of the American Heart Association

Published: July 25, 2026

Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations.

Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations.

Journal: The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians

Published: July 22, 2026

Empagliflozin and functional capacity in patients at risk of heart failure.

Empagliflozin and functional capacity in patients at risk of heart failure.

Journal: American heart journal

Published: July 17, 2026

Showing 1-12 of 5,465

Last Updated: 09/26/2026